A214 Pill - yellow oval, 10mm
Pill with imprint A214 is Yellow, Oval and has been identified as Levetiracetam Extended Release 750 mg. It is supplied by Anchen Pharmaceuticals, Inc. .
Levetiracetam is used in the treatment of Seizures; Epilepsy and belongs to the drug class pyrrolidine anticonvulsants. Risk cannot be ruled out during pregnancy. Levetiracetam 750 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for A214
Levetiracetam Extended Release
- Imprint
- A214
- Strength
- 750 mg
- Color
- Yellow
- Size
- 10.00 mm
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- Pyrrolidine anticonvulsants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Anchen Pharmaceuticals, Inc.
- National Drug Code (NDC)
- 10370-0214 (Discontinued)
- Inactive Ingredients
-
silicon dioxide,
hydroxypropyl cellulose,
magnesium stearate,
polyvinyl alcohol,
magnesium silicate,
polyethylene glycol,
titanium dioxide,
ferric oxide yellow,
ferric oxide red
Note: Inactive ingredients may vary.
Related images for "A214"
More about levetiracetam
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (423)
- Drug images
- Latest FDA alerts (5)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: pyrrolidine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Levetiracetam oral/injection drug information
- Levetiracetam (Intravenous) (Advanced Reading)
- Levetiracetam (Oral) (Advanced Reading)
- Levetiracetam Extended-Release Tablets
- Levetiracetam Injection
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Professional resources
- Levetiracetam monograph
- Levetiracetam Extended Release Tablets (FDA)
- Levetiracetam Injection (FDA)
- Levetiracetam Injection, Concentrate (FDA)
- Levetiracetam Solution (FDA)
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
